Lundbeckfonden Emerge

Facilitates the birth of Danish biotech companies

Lundbeckfonden Emerge is the early stage investment unit of Lundbeckfonden. Emerge has the ambition to enable commercialisation of pioneering life science research by way of investment and active project involvement.

We seek out projects primarily arising from Danish research. Emerge creates value in innovative projects through close collaboration with founders by way of detailed analysis prior to engagement, direct financing and active project participation. We seek to identify and initiate development of scientific opportunities which in depth analysis demonstrates have high commercial potential. In addition to return on investment, Emerge aims to help grow a healthy Danish biotech ecosystem for the long term. This means translating innovation into growth and jobs.

In 2015 Emerge announced its full strategy and a new fund of DKK 300 million to be invested over 4 years aimed at creating 5 to 6 new investments / companies and with the ability to support them with appropriate refinancing and support as they develop. Emerge has an active portfolio of biotech investments.

Who we are

Lundbeckfonden Emerge is run by a small team with extensive experience in building new biotech companies, operational and business experience and a substantial network within life science and venture capital. We not only offer financing for selected cases but also offers seasoned advice or direct participation in new ventures, as part of our unique model to optimize the outcome of the venture to the benefit of all stakeholders.

We will seek to develop select projects together with founders and will take on an active role from mentoring to active project management. Each project is considered on its merits and our level of involvement tailored to best fit the process.

Investment opportunities

Our interests and investments cover a wide life sciences field and in all cases the projects are supported by solid scientific data and potential intellectual property. The main objective is to turn scientific discoveries and early stage opportunities into new biotech businesses and ultimately commercial successes.

Provided an innovative life sciences idea is based on solid science with relevant intellectual property potential, the field of investment can be wide as can the source of the project.

Should you be interested in discussing your project or company with Lundbeckfonden Emerge, please send non-confidential material to: emerge@lundbeckfonden.com

Lundbeckfonden Emerge

News

Dermtreat secures GMP manufacturing
4. September 2017
Dermtreat Raises USD 17.7 mill. From Sofinnova Ventures, Novo A/S and Lundbeckfonden
8. May 2017
Rare Neuromuscular Disease Company NMD Pharma Raises USD 3 Million in Seed Financing Round
13. June 2016